The Efficacy and Safety of Tislelizumab Combined With Anlotinib and S1 Plus Oxaliplatin as Neoadjuvant Therapy for the Locally Advanced Adenocarcinoma of Esophagogastric Junction

Registration Number
NCT06396585
Lead Sponsor
Fujian Cancer Hospital
Brief Summary

To evaluate the efficacy and safety of tislelizumab combined with antilotinib and SOX regimen for neoadjuvant treatment of locally advanced esophagogastric junction cancer

Detailed Description

Not available

Recruitment & Eligibility

Status
NOT_YET_RECRUITING
Sex
All
Target Recruitment
28
Inclusion Criteria
  • Female and male patient ≥ 18 and ≤ 75 years.
  • Histologically confirmed, medically operable, resectable adenocarcinoma of the gastroesophageal junction (AEG, Siewert II-III),uT3, uT4a, uT4b any N category, M0, or any T N+ M0 patient
  • ECOG≤1
  • No previous surgical treatment, anti-tumor chemoradiotherapy/immunotherapy was performed.
  • Exclusion of distant metastases by CT or MRI of abdomen, pelvis, and thorax, bone scan or MRI (if bone metastases are suspected due to clinical signs).
  • Preoperative endoscopic examination confirmed no positive peritoneal implantation metastasis and exfoliated cells.
  • The expected survival time is more than 6 months.
  • Women of childbearing age shall be those who agree to use contraception (such as intrauterine devices, contraceptives or condoms) during the study and for 6 months after the end of the study; those who have a negative serum or urine pregnancy test within 7 days before study enrollment and must be non-lactating; and men who agree to use contraception during the study and for 6 months after the end of the study.
  • Hematological, hepatic and renal function parameters adequate to allow surgical procedure and chemotherapy
  • Patient able and willing to provide written informed consent and to comply with the study protocol and with the planned surgical procedures
Read More
Exclusion Criteria
  • Diagnosis of malignant diseases other than gastric cancer within 5 years prior to first administration (excluding radical basal cell carcinoma of the skin, squamous carcinoma of the skin, and/or radical resectable carcinoma in situ).
  • Significant clinical bleeding symptoms or clear bleeding tendency, such as gastrointestinal bleeding, hemorrhagic gastric ulcer or vasculitis, etc. occurred within 3 months before enrollment. If fecal occult blood was positive at baseline, reexamination could be performed, if it was still positive after reexamination, gastroscopy was required.
  • Prior treatment: anti-PD-1, anti-PD-L1, or anti-PD-L2 drugs or drugs that target another stimulating or co-inhibiting T-cell receptor (e.g., CTLA-4, OX-40, CD137).
  • A history of immunodeficiency, including HIV testing positive.
  • Is currently participating in an interventional clinical study or has been treated with another study drug or study device in the 4 weeks prior to initial dosing.
  • Patients who had a history of cardiovascular and cerebrovascular diseases and were still taking thrombolytic drugs or anticoagulants orally.
  • HER2 positive is known.
  • Patients with previous gastrointestinal perforation, abdominal abscess or recent intestinal obstruction (within 3 months) or imaging or clinical symptoms suggesting intestinal obstruction.
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Tislelizumab combined with anlotinib chemotherapyTislelizumab-
Tislelizumab combined with anlotinib chemotherapyAnlotinib-
Tislelizumab combined with anlotinib chemotherapyOxaliplatin-
Tislelizumab combined with anlotinib chemotherapyTegafur-
Primary Outcome Measures
NameTimeMethod
Pathological complete response4 weeks after surgery

Total tumor regression rate under pathologyPrimary tumor or lymph node surgery specimen pathological examination without residual tumor cell

Secondary Outcome Measures
NameTimeMethod
Major pathological response4 weeks after surgery

Total/moderate tumor regression rate under pathologyPrimary tumor or lymph node surgery specimen pathological examination without residual tumor cell

Objective Response Rate (ORR)At the end of Cycle 3 (each cycle is 21 days)

Objective Response Rate Determine the tumor shrinkage rate, tumor boundary and the adhesion of tumor

Trial Locations

Locations (1)

Fujian cancer hospital

🇨🇳

Fuzhou, Fujian, China

© Copyright 2024. All Rights Reserved by MedPath